目的 研究美洛昔康咀嚼片在比格犬体内的药动学和生物等效性。方法 12只健康成年比格犬随机分为2组，采用双周期交叉实验设计，分别口服测试片剂和参比片剂2 mg，用RP-HPLC方法测定血浆中美洛昔康的浓度，应用3P97软件计算药动学参数，并进行两种制剂的生物等效性评价。结果 测试片剂和参比片剂的AUC_{0~96 h}分别为（2.85±0.64）和（2.79±0.48）μg/mL·h，T_max分别为（4.33±0.65）和（4.16±0.71）h，C_max分别为（0.091±0.017）和（0.086±0.021）μg/mL，t_1/2分别为（26.08±3.64）和（26.94±4.21）h，两者的lnAUC和lnC_max经双单侧t检验证明差异无统计意义。结论 测试片剂与国外上市的参比片剂具有生物等效性，其平均相对生物利用度为（98.0±9.76）%。

Objective To investigate in vivo pharmacokinetics and bioequivalence of Meloxicam Chewable Tablets in healthy Beagle's dogs. Method Twelve healthy adult Beagle's dogs were randomized into two groups. Using the double-preparation, double-cycle, cross-over method and administering orally of testing and reference tablet (2 mg) respectively. The plasma concentration of meloxicam was determinated by RP-HPLC. The 3P97 software was adopted to calculate the pharmacokinetic parameters and evaluate the bioequivalence of two preparations. Results The area under the curves (AUC_{0-96 h}) of the testing tablets and innovator tablets were (2.85±0.64) and (2.79±0.48) μg/mL·h. The peak time (T_max) was (4.33±0.65) and (4.16±0.71) h. The peak concentration (C_max) was (0.091±0.017) and (0.086±0.021) μg/mL. The half time (t_1/2) was (26.08±3.64) and (26.94±4.21) h. After the double unilateral t test, there was no statistical significance in the difference of lnAUC and lnC_max between the testing tablets and innovator tablets. Conclusion The testing tablets and innovator tablets are bioequivalent. The relative bioavailability of generic tablet is (98.0±9.76)%.